MA52542A - Thérapie cellulaire adoptive - Google Patents

Thérapie cellulaire adoptive

Info

Publication number
MA52542A
MA52542A MA052542A MA52542A MA52542A MA 52542 A MA52542 A MA 52542A MA 052542 A MA052542 A MA 052542A MA 52542 A MA52542 A MA 52542A MA 52542 A MA52542 A MA 52542A
Authority
MA
Morocco
Prior art keywords
cell therapy
adoptive cell
adoptive
therapy
cell
Prior art date
Application number
MA052542A
Other languages
English (en)
Inventor
James Brian Rottman
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of MA52542A publication Critical patent/MA52542A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA052542A 2018-04-13 2019-04-12 Thérapie cellulaire adoptive MA52542A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862657388P 2018-04-13 2018-04-13

Publications (1)

Publication Number Publication Date
MA52542A true MA52542A (fr) 2021-02-24

Family

ID=68163824

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052542A MA52542A (fr) 2018-04-13 2019-04-12 Thérapie cellulaire adoptive

Country Status (4)

Country Link
US (3) US12036256B2 (fr)
EP (1) EP3781188A4 (fr)
MA (1) MA52542A (fr)
WO (1) WO2019200316A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12036256B2 (en) 2018-04-13 2024-07-16 Regeneron Pharmaceuticals, Inc. Adoptive cellular therapy
CN113164484A (zh) * 2018-11-29 2021-07-23 复诺健生物科技加拿大有限公司 具有降低的神经毒性的hsv载体
US20210077554A1 (en) * 2019-09-13 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells
CN111218426A (zh) * 2020-02-26 2020-06-02 华东师范大学 一种克服肿瘤微环境car-t细胞的制备及其用途
WO2021202581A1 (fr) * 2020-03-30 2021-10-07 WUGEN, Inc. Cellules immunitaires modifiées pour thérapie cellulaire adoptive
WO2021211902A2 (fr) * 2020-04-15 2021-10-21 Humane Genomics Virus oncolytiques artificiels et procédés associés
WO2021240533A1 (fr) * 2020-05-29 2021-12-02 National Institute Of Immunology Signature de micro-arn dépendant de l'endommagement de l'adn pour des cancers, procédés et utilisations associés
CN112481222B (zh) * 2020-11-30 2024-01-02 中国医学科学院医学生物学研究所 一种条件复制型重组单纯疱疹病毒、疫苗及其应用
CN112840020B (zh) * 2021-01-13 2023-03-17 嘉兴允英医学检验有限公司 溶瘤病毒及其应用
CN114788865B (zh) * 2021-01-25 2023-09-01 中国科学院上海营养与健康研究所 miR-378作为胆固醇稳态调控靶点的应用
WO2022214014A1 (fr) * 2021-04-08 2022-10-13 Immvira Biopharmaceuticals Co., Limited Virus herpès simplex oncolytique génétiquement modifié délivrant une chimiokine et un antigène spécifique/associé à une tumeur
WO2023034867A1 (fr) * 2021-08-31 2023-03-09 Oncorus, Inc. Virus de l'herpès oncolytique génétiquement modifié
CN118389408B (zh) * 2024-06-26 2024-11-29 淇嘉科技(苏州)有限公司 炎症性肠病及纤维化体外精准模拟方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795695A1 (fr) 2010-04-09 2011-10-13 The University Of Tokyo Virus de vaccine recombinant regule par micro-arn et utilisation de celui-ci
ES2810800T3 (es) 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
CN108473950A (zh) * 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
AR107469A1 (es) * 2016-01-27 2018-05-02 Oncorus Inc Vectores virales oncolíticos y sus usos
EP3468588A4 (fr) * 2016-06-14 2019-12-11 University of Pittsburgh - of The Commonwealth System of Higher Education Expression de protéines de ligand d'activation de nkg2d pour sensibiliser les cellules cancéreuses à une attaque par des cellules immunitaires cytotoxiques
US12036256B2 (en) 2018-04-13 2024-07-16 Regeneron Pharmaceuticals, Inc. Adoptive cellular therapy

Also Published As

Publication number Publication date
WO2019200316A1 (fr) 2019-10-17
US12036256B2 (en) 2024-07-16
US20260053872A1 (en) 2026-02-26
US20250009822A1 (en) 2025-01-09
EP3781188A4 (fr) 2022-03-02
EP3781188A1 (fr) 2021-02-24
US20210252084A1 (en) 2021-08-19
US12397028B2 (en) 2025-08-26

Similar Documents

Publication Publication Date Title
MA52542A (fr) Thérapie cellulaire adoptive
EP3802802A4 (fr) Thérapie cellulaire
IL281810A (en) Implantable devices for cell therapy and related methods
DK3886875T3 (da) Behandlingsfremgangsmåder under anvendelse af adoptiv celleterapi
IL269380A (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
IL258844A (en) Methods for culturing cells and kits and apparatus for same
EP3775166A4 (fr) Méthodes perfectionnées de thérapie par cellules spécifiques de l'antigène
SG11202101996QA (en) Improved therapeutic t cell
LT3740504T (lt) Cd70 kompleksinė terapija
EP3394250A4 (fr) Reprogrammation cellulaire
IL282531A (en) Anti-liv1 immune cell cancer therapy
EP3647407A4 (fr) Dispositif de culture cellulaire
PL3907773T3 (pl) Akumulator
HUE057249T2 (hu) Akkumulátortelep
EP4059081C0 (fr) Désactivation de batterie
HUE064241T2 (hu) Akkumulátor
EP3645020A4 (fr) Compositions et procédés pour la thérapie cellulaire adoptive
HUE069188T2 (hu) Akkumulátor
EP3645019A4 (fr) Compositions et méthodes pour thérapie cellulaire adoptive
EP4013854A4 (fr) Procédés de culture cellulaire
EP3843748C0 (fr) Polythérapie
EP3737392A4 (fr) Thérapie de reprogrammation cellulaire
EP3941490A4 (fr) Thérapie cellulaire adoptive
IL276979A (en) Macro-encapsulation of medicinal cells, devices and methods in their use
DE112019005840A5 (de) Batteriezelle